The present Invention relates to a pharmaceutical dosage formulation comprising of lopinavir and ritonavir whose characteristic lies in the reduction or elimination of gastrointestinal adverse events and that it is possible to have a form of dosage can be car Gar with more active ingredient to reduce the amount of pill to take patientsAmong other described in the file.Mevcut buluş farmasötik bir dozaj formülasyonu ve daha belirgin olarak bir HIV proteaz inhibitörü içeren farmasötik bir dozaj formülasyonu sağlar.